US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% SDEV $7.48 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00%
FinancialContent

Amgen (NQ:AMGN)

403.04 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
72 73 Next >
News headline image
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease ↗
The company's drug led to an improvement in diplopia, or double vision, an area where Amgen's Tepezza hasn't worked. 
Via Investor's Business Daily
News headline image
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? ↗
The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
Via Investor's Business Daily
News headline image
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ↗
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
News headline image
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over ↗
Via The Motley Fool
Topics Stocks
News headline image
Unpacking the Latest Options Trading Trends in Amgen ↗
 
Via Benzinga
News headline image
Demystifying Amgen: Insights From 13 Analyst Reviews ↗
 
Via Benzinga
News headline image
Is Amgen Still a Top Dividend Stock? ↗
Via The Motley Fool
News headline image
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip? ↗
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer ↗
Via The Motley Fool
News headline image
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗
Looking for reliable income in the stock market? You might want to consider the top Dogs of the Dow in December. Here's what you need to know about this trio of blue-chip stocks. 
Via The Motley Fool
Topics Stocks
News headline image
MarketBeat Week in Review – 12/2 - 12/6
Equities continued their post-election rally after Friday’s solid November jobs report and all signs point to the rally in stocks extending into 2025 
Via MarketBeat
Topics Economy Government Immigration
News headline image
Why Amgen's Weight Loss Result Is a Win for Eli Lilly ↗
Via The Motley Fool
News headline image
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?
Results for Amgen's weight loss drug Maritide were highly anticipated, but fell short. However, MariTide could still turn the tables in future studies. 
Via MarketBeat
News headline image
13 Healthcare Sector Stocks With Healthy Valuation ↗
We are looking for value in the Healthcare Sector because we are still in a strong bull market that has been not only one of the longest on record, but also has seen the S&P 500 get to one of its lofty... 
Via Talk Markets
Topics Stocks Stocks / Equities
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy? ↗
Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable. 
Via The Motley Fool
News headline image
Eli Lilly Just Got a Bundle of Good News: Time to Buy? ↗
Via The Motley Fool
News headline image
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance ↗
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy? ↗
Via The Motley Fool
News headline image
Stock Market Hits Highs Despite Trump Tariff Threats, Nvidia, Tech Turkeys: Weekly Review ↗
The Nasdaq isn't at a high, but it isn't far off either. 
Via Investor's Business Daily
Topics Government
News headline image
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data? ↗
Via The Motley Fool
News headline image
2 Generic Drug Stocks Ready to Surge in 2025
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success. 
Via MarketBeat
Topics Government Intellectual Property
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday? ↗
The U.S. stock market traded mixed on Tuesday morning, with major indices showing tight movements as investors awaited the release of the Federal Reserve's November meeting minutes. 
Via Benzinga
Topics Economy
News headline image
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs ↗
The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis. 
Via Benzinga
News headline image
Pain In Retail ↗
It’s been a relatively busy morning for earnings, especially from retailers. Of the ten companies reporting, six topped EPS forecasts, seven beat sales forecasts, but two, Best Buy and Kohl’s lowered... 
Via Talk Markets
Topics Stocks / Equities
News headline image
Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test ↗
Over the course of a year, Amgen's MariTide helped patients lose about 20% of their body weight. 
Via Investor's Business Daily
News headline image
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau ↗
Amgen's Phase 2 MariTide trial showed ~20% weight loss at 52 weeks, cardiometabolic improvements, and no significant safety issues. 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
72 73 Next >